Source:http://linkedlifedata.com/resource/pubmed/id/18972629
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2008-10-29
|
| pubmed:abstractText |
Data on the use of levosimendan in patients with myocardial infarction related cardiogenic shock already under combined catecholamine treatment and intra-aortic balloon counterpulsation (IABP) are scarce. Seven consecutive patients with refractory cardiogenic shock after ST-elevation myocardial infarction, multi-organ dysfunction syndrome and under maximal intensive care (combined catecholamine treatment, IABP) were treated with levosimendan (bolus 12 microg/kg i.v., thereafter 0.1 microg/kg over 24 h). Hemodynamic effects were registered invasively and monitored over 72h post infusion. Therapy with levosimendan significantly reduced required epinephrine dose after 48h (P=0.02 versus baseline). Norepinephrine dose had to be increased during the first 12 h of levosimendan (+25%; P=ns), but was significantly reduced at 72 h compared to baseline (median 0.14 versus 0.06 microg/kg/min after 72 h; P<0.05). Cardiac power output increased (baseline 0.6 versus 1.1 > or = 48 h after infusion; P<0.01) and systemic vascular resistance decreased (median 1294 dyn*s*cm-5 at baseline versus 858 dyn*s*cm-5 at 24 h; P<0.05) after levosimendan infusion. IABP therapy could be weaned in all patients during 5 days after infusion and all patients survived the cardiogenic shock (ICU mortality 29%). Levosimendan as an adjunctive, rescue therapy in patients with severe cardiogenic shock may be safe with beneficial effects on hemodynamics over 72 h.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cardiotonic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Hydrazones,
http://linkedlifedata.com/resource/pubmed/chemical/Norepinephrine,
http://linkedlifedata.com/resource/pubmed/chemical/Pyridazines,
http://linkedlifedata.com/resource/pubmed/chemical/Vasoconstrictor Agents,
http://linkedlifedata.com/resource/pubmed/chemical/simendan
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1748-2941
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
10
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
185-90
|
| pubmed:dateRevised |
2009-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:18972629-Aged,
pubmed-meshheading:18972629-Cardiac Output,
pubmed-meshheading:18972629-Cardiotonic Agents,
pubmed-meshheading:18972629-Combined Modality Therapy,
pubmed-meshheading:18972629-Female,
pubmed-meshheading:18972629-Hemodynamics,
pubmed-meshheading:18972629-Humans,
pubmed-meshheading:18972629-Hydrazones,
pubmed-meshheading:18972629-Intra-Aortic Balloon Pumping,
pubmed-meshheading:18972629-Male,
pubmed-meshheading:18972629-Middle Aged,
pubmed-meshheading:18972629-Myocardial Infarction,
pubmed-meshheading:18972629-Norepinephrine,
pubmed-meshheading:18972629-Prospective Studies,
pubmed-meshheading:18972629-Pyridazines,
pubmed-meshheading:18972629-Shock, Cardiogenic,
pubmed-meshheading:18972629-Vasoconstrictor Agents,
pubmed-meshheading:18972629-Ventricular Dysfunction, Left
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
Levosimendan as rescue therapy in severe cardiogenic shock after ST-elevation myocardial infarction.
|
| pubmed:affiliation |
Medizinische Klinik und Poliklinik I, University Medical Center Munich-Grosshadern, Ludwig-Maximilians University of Munich, Munich, Germany.
|
| pubmed:publicationType |
Journal Article
|